期刊文献+

左旋奥拉西坦在脑缺血再灌注模型大鼠体内的药动学研究 被引量:3

Pharmacokinetic study of S-oxiracetam in cerebral ischemia-reperfusion model rats
下载PDF
导出
摘要 目的:建立大鼠血浆中左旋奥拉西坦的HPLC-UV测定方法,比较其在正常大鼠和脑缺血再灌注模型大鼠体内的药代动力学特征的差异。方法:采用茴拉西坦作为内标,HPLC-UV法测定,色谱柱为APS-2 HYPERSIL柱(250 mm×4.6 mm,5μm),流动相为水-乙腈(12:88),流速1.0 mL·min-1,检测波长214 nm,柱温25℃,采用DAS 2.0软件计算药代动力学参数。结果:血浆中左旋奥拉西坦在0.5~100.0μg·mL-1范围内线性关系良好(r2=0.996 8),方法的提取回收率、精密度、准确度和稳定性均符合生物样品的测定要求。正常对照组大鼠和脑缺血再灌注模型组大鼠的AUC0-t、AUC0-∞、MRT0-t、t1/2z、CLz和Vz具有显著性差异(P <0.05)。结论:该方法灵敏准确、简便、专属性强,适用于左旋奥拉西坦在大鼠体内的药代动力学研究,脑缺血再灌注模型组较正常组大鼠药-时曲线下面积增加,消除速率减慢。 Objective: To establish the HPLC method for the determination of S-oxiracetam in rat plasma and to fgure out the pharmacokinetic differences between the normal rats and the cerebral ischemia-reperfusion model rats. Methods: Aniracetam was used as internal standard. The concentrations of S-oxiracetam in rat plasma were measured by HPLC-UV, which was performed on a APS-2 HYPERSIL column (250 mm × 4.6 mm, 5 μm) with the mobile phase of water-acetonitrile (12 : 88) at a fow rate of 1.0 mL·min-1. The detection wavelength was set at 214 nm and the column temperature was 25 ℃. The pharmacokinetic parameters were calculated by DAS 2.0 software. Results: The calibration curve of S-oxiracetam was linear in the range of 0.5 – 100.0 μg·mL-1 (r^2 = 0.996 8). The mean recoveries, precision, accuracy and the stability were in line with the biological sample measurement requirements. The AUC0-t, AUC0-∞, MRT0-t, t1/2z, CLz and Vz of S-oxiracetam in normal rats were signifcantly different from those in cerebral ischemia-reperfusion model rats. Conclusion: The method was proved to be sensitive, accurate, simple and had strong specificity, which was suitable for the pharmacokinetic study of S-oxiracetam. Compared with normal group rats, the AUC of S-oxiracetam increased and the elimination rate of S-oxiracetam slowed down in cerebral ischemia-reperfusion model rats.
作者 利玲 胡秀 利莉 LI Ling;HU Xiu;LI Li(Huangshi Central Hospital,Affliated Hospital of Hubei Polytechnic University,Edong Healthcare Group,Huangshi 435000,China;Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention,Huangshi 435000,China)
出处 《中国药物应用与监测》 CAS 2018年第5期270-274,共5页 Chinese Journal of Drug Application and Monitoring
关键词 左旋奥拉西坦 高效液相色谱法 脑缺血再灌注 药代动力学 S-oxiracetam High performance liquid chromatography Cerebral ischemia-reperfusion Pharmacokinetics
  • 相关文献

参考文献5

二级参考文献42

  • 1付琳,邱相君,代宗顺,侯淑贤,庞雪冰,吴怀安.奥卡西平片的人体相对生物利用度研究[J].中国药科大学学报,2004,35(3):244-247. 被引量:18
  • 2谢建伟,苏为科,周兆良.奥卡西平合成路线图解[J].中国医药工业杂志,2005,36(2):123-125. 被引量:5
  • 3李相杰.利福喷丁、利福平治疗菌阳肺结核的疗效观察[J].临床肺科杂志,2006,11(3):380-380. 被引量:12
  • 4陈奇.中药药理研究方法学[M].北京:人民卫生出版社,1996.33-34. 被引量:309
  • 5Xie X Y, Wang R, Shi Y P. Chemical constituents from the fruits of Comus officinalis [ J ]. Biochem Syst Ecol, 2012, 45(7) :120-123. 被引量:1
  • 6Wang W, Sun F L, An Y, et al. Morroniside protects human neuroblastoma SH-SY5Y ceils against hydrogen peroxide-induced cytotoxicity [ J ]. Eur J Pharmacol, 2009, 613 (1/3) :19-23. 被引量:1
  • 7Wang W, Huang W T, Li L, et al. Morroniside prevents peroxide-induced apoptosis by induction of endogenous glutathione in human neuroblastoma cells [J]. Cell Mol Neurobiol, 2008, 28 (2) :293-305. 被引量:1
  • 8Wang W, Xu J D, Li L, et al. Neuroproteetive effect of morronisidc on focal cerebral ischemia in rats[ J ]. Brain Res Bull, 2010, 83 (5) :196-201. 被引量:1
  • 9Longa E Z, Weinstein P R, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats[J]. Stroke, 1989, 20(1):84-91. 被引量:1
  • 10Bederson J B, Pitts L H, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination [ J]. Stroke, 1986, 17(3) :472-476. 被引量:1

共引文献37

同被引文献42

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部